According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “
EARS stock traded up $0.02 during midday trading on Tuesday, reaching $2.63. The company’s stock had a trading volume of 58,500 shares, compared to its average volume of 161,738. The company’s fifty day moving average price is $2.73. Auris Medical has a 1 year low of $2.41 and a 1 year high of $39.40. The stock has a market cap of $4.83 million, a price-to-earnings ratio of -0.18 and a beta of -0.50.
About Auris Medical
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Recommended Story: How interest rates affect municipal bond prices
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.